Previous close | 7.50 |
Open | N/A |
Bid | 8.40 |
Ask | 10.50 |
Strike | 15.00 |
Expiry date | 2024-06-21 |
Day's range | 7.50 - 7.50 |
Contract range | N/A |
Volume | |
Open interest | 3 |
We recently compiled a list of the Wall Street Analysts Just Trimmed Price Targets for These 10 Stocks. In this article, we will examine how Shattuck Labs, Inc. (NASDAQ:STTK) compares to other stocks whose price targets have been recently reduced by analysts. On Tuesday, US stock futures remained stable, reflecting investor optimism following a significant rally […]
Shattuck (STTK) will now focus on higher-risk myelodysplastic syndromes and TP53 mutant acute myeloid leukemia indications for lead candidate SL-172154, following encouraging interim data from the phase IB dose expansion study.
– Observed 67% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete remission (CR)/marrow complete remission (mCR) rate of 58% and median overall survival had not yet been reached – – Observed 43% ORR in frontline TP53m AML patients, 33% CR/complete remission with incomplete hematologic recovery (CRi) and median overall survival had not yet been reached – – SL-172154 demonstrated a manageable interim safety profile in combination with AZA –